General MedicationsINJECTIONStandard
DDAVP
DESMOPRESSIN ACETATE
Standard Dose
0.004MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview DDAVP is listed in Drugs@FDA under application 018938 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient DESMOPRESSIN ACETATE Form and strength INJECTABLE;INJECTION - 0.004MG/ML Sponsor NORDIC PHARMA Submission history Latest submission status date: 2022-07-21 00:00:00.
Structured Monograph
Clinical summary
Approval overview DDAVP is listed in Drugs@FDA under application 018938 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient DESMOPRESSIN ACETATE Form and strength INJECTABLE;INJECTION - 0.004MG/ML Sponsor NORDIC PHARMA Submission history Latest submission status date: 2022-07-21 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.